Skip to main content
SpringerLink
Log in

Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes

  • Research Article
  • Published:
Archives of Pharmacal Research Aims and scope Submit manuscript

Abstract

MAM-2201, a synthetic cannabinoid, is a potent agonist of the cannabinoid receptors and is increasingly used as an illicit recreational drug. The inhibitory effects of MAM-2201 on major drug-metabolizing enzymes such as cytochrome P450s (CYPs) and uridine 5′-diphospho-glucuronosyltransferases (UGTs) have not yet been investigated although it is widely abused, sometimes in combination with other drugs. We evaluated the inhibitory effects of MAM-2201 on eight major human CYPs (CYPs 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4) and six UGTs (UGTs 1A1, 1A3, 1A4, 1A6, 1A9, and 2B7) of pooled human liver microsomes; we thus explored potential MAM-2201-induced drug interactions. MAM-2201 potently inhibited CYP2C9-catalyzed diclofenac 4′-hydroxylation, CYP3A4-catalyzed midazolam 1′-hydroxylation, and UGT1A3-catalyzed chenodeoxycholic acid 24-acyl-glucuronidation, with K i values of 5.6, 5.4 and 5.0 µM, respectively. MAM-2201 exhibited mechanism-based inhibition of CYP2C8-catalyzed amodiaquine N-de-ethylation with K i and k inact values of 1.0 µM and 0.0738 min−1, respectively. In human liver microsomes, MAM-2201 (50 µM) negligibly inhibited CYP1A2, CYP2A6, CYP2B6, CYP2C19, CYP2D6, UGT1A1, UGT1A4, UGT1A6, UGT1A9, and UGT2B7. Based on these in vitro results, we conclude that MAM-2201 has the potential to trigger in vivo pharmacokinetic drug interactions when co-administered with substrates of CYP2C8, CYP2C9, CYP3A4, and UGT1A3.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  • Al Saabi A, Allorge D, Sauvage FL, Tournel G, Gaulier JM, Marquet P, Picard N (2013) Involvement of UDP-glucuronosyltransferases UGT1A9 and UGT2B7 in ethanol glucuronidation, and interactions with common drugs of abuse. Drug Metab Dispos 41:568–574

    Article  CAS  PubMed  Google Scholar 

  • Alonen A, Finel M, Kostiainen R (2008) The human UDP-glucuronosyltransferase UGT1A3 is highly selective towards N2 in the tetrazole ring of losartan, candesartan, and zolarsartan. Biochem Pharmacol 76:763–772

    Article  CAS  PubMed  Google Scholar 

  • Andreeva-Gateva PA, Nankova VH, Angelova VT, Gatev TN (2015) Synthetic cannabimimetics in Bulgaria 2010-2013. Drug Alcohol Depend 157:200–204

    Article  CAS  PubMed  Google Scholar 

  • Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) ‘Spice’ and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectrom 44:832–837

    Article  PubMed  Google Scholar 

  • Cerny MA (2016) Prevalence of non–cytochrome P450–mediated metabolism in Food and Drug Administration–approved oral and intravenous drugs: 2006–2015. Drug Metab Dispos 44:1246–1252

    Article  CAS  PubMed  Google Scholar 

  • Chimalakonda KC, Seely KA, Bratton SM, Brents LK, Moran CL, Endres GW, James LP, Hollenberg PF, Prather PL, Radominska-Pandya A, Moran JH (2012) Cytochrome P450-mediated oxidative metabolism of abused synthetic cannabinoids found in K2/Spice: identification of novel cannabinoid receptor ligands. Drug Metab Dispos 40:2174–2184

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Chung H, Choi H, Heo S, Kim E, Lee J (2014) Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013. Forensic Toxicol 32:82–88

    Article  CAS  Google Scholar 

  • Derungs A, Schwaninger AE, Mansella G, Bingisser R, Kraemer T, Liechti ME (2013) Symptoms, toxicities, and analytical results for a patient after smoking herbs containing the novel synthetic cannabinoid MAM-2201. Forensic Toxicol 31:164–171

    Article  Google Scholar 

  • Erichsen TJ, Aehlen A, Ehmer U, Kalthoff S, Manns MP, Strassburg CP (2010) Regulation of the human bile acid UDP-glucuronosyltransferase 1A3 by the farnesoid X receptor and bile acids. J Hepatol 52:570–578

    Article  CAS  PubMed  Google Scholar 

  • Fattore L, Fratta W (2011) Beyond THC: the new generation of cannabinoid designer drugs. Front Behav Neurosci 5:60

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Foti RS, Dalvie DK (2016) Cytochrome P450 and non–cytochrome P450 oxidative metabolism: contributions to the pharmacokinetics, safety, and efficacy of xenobiotics. Drug Metab Dispos 44:1229–1245

    Article  CAS  PubMed  Google Scholar 

  • Helander A, Backberg M, Hulten P, Al-Saffar Y, Beck O (2014) Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project. Forensic Sci Int 243:23–29

    Article  CAS  PubMed  Google Scholar 

  • Jeong ES, Kim YW, Kim HJ, Shin HJ, Shin JG, Kim KH, Chi YH, Paik SH, Kim DH (2015) Glucuronidation of fimasartan, a new angiotensin receptor antagonist, is mainly mediated by UGT1A3. Xenobiotica 45:10–18

    Article  CAS  PubMed  Google Scholar 

  • Kim JH, Kim HS, Kong TY, Lee JY, Kim JY, In MK, Lee HS (2016) In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s. J Pharm Biomed Anal 119:50–58

    Article  CAS  PubMed  Google Scholar 

  • Kim JH, Kwon SS, Kong TY, Cheong JC, Kim HS, In MK, Lee HS (2017) AM-2201 inhibits multiple cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 22:E443

    Article  PubMed  Google Scholar 

  • Kong TY, Kim JH, Choi WG, Lee JY, Kim HS, Kim JY, In MK, Lee HS (2017a) Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes. Anal Bioanal Chem 409:1667–1680

    Article  CAS  PubMed  Google Scholar 

  • Kong TY, Kim JH, Kim JY, In MK, Choi KH, Kim HS, Lee HS (2017b) Rapid analysis of drugs of abuse and their metabolites in human urine using dilute and shoot liquid chromatography–tandem mass spectrometry. Arch Pharm Res 40:180–196

    Article  CAS  PubMed  Google Scholar 

  • Kronstrand R, Roman M, Andersson M, Eklund A (2013) Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol 37:534–541

    Article  CAS  PubMed  Google Scholar 

  • Kwon SS, Kim JH, Jeong HU, Cho YY, Oh SR, Lee HS (2016) Inhibitory effects of aschantin on cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferase enzyme activities in human liver microsomes. Molecules 21:E554

    Article  PubMed  Google Scholar 

  • Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW, Zhou SF (2009) Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Curr Drug Metab 10:1009–1047

    Article  CAS  PubMed  Google Scholar 

  • Langer N, Lindigkeit R, Schiebel HM, Ernst L, Beuerle T (2014) Identification and quantification of synthetic cannabinoids in ‘spice-like’ herbal mixtures: a snapshot of the German situation in the autumn of 2012. Drug Test Anal 6:59–71

    Article  CAS  PubMed  Google Scholar 

  • Lonati D, Buscaglia E, Papa P, Valli A, Coccini T, Giampreti A, Petrolini VM, Vecchio S, Serpelloni G, Locatelli CA (2014) MAM-2201 (analytically confirmed) intoxication after “Synthacaine” consumption. Ann Emerg Med 64:629–632

    Article  PubMed  Google Scholar 

  • Musshoff F, Madea B, Kernbach-Wighton G, Bicker W, Kneisel S, Hutter M, Auwarter V (2014) Driving under the influence of synthetic cannabinoids (“Spice”): a case series. Int J Legal Med 128:59–64

    Article  PubMed  Google Scholar 

  • Nakajima JI, Takahashi M, Nonaka R, Seto T, Suzuki J, Yoshida M, Kanai C, Hamano T (2011) Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitro [35S]GTPγS binding assays. Forensic Toxicol 29:132–141

    Article  CAS  Google Scholar 

  • Polasek TM, Elliot DJ, Lewis BC, Miners JO (2004) Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro. J Pharmacol Exp Ther 311:996–1007

    Article  CAS  PubMed  Google Scholar 

  • Roth MD, Marques-Magallanes JA, Yuan M, Sun W, Tashkin DP, Hankinson O (2001) Induction and regulation of the carcinogen-metabolizing enzyme CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell Mol Biol 24:339–344

    Article  CAS  PubMed  Google Scholar 

  • Saito T, Namera A, Miura N, Ohta S, Miyazaki S, Osawa M, Inokuchi S (2013) A fatal case of MAM-2201 poisoning. Forensic Toxicol 31:333–337

    Article  Google Scholar 

  • Seely KA, Lapoint J, Moran JH, Fattore L (2012) Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids. Prog Neuropsychopharmacol Biol Psychiatry 39:234–243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Stout SM, Cimino NM (2014) Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 46:86–95

    Article  CAS  PubMed  Google Scholar 

  • Su MK, Seely KA, Moran JH, Hoffman RS (2015) Metabolism of classical cannabinoids and the synthetic cannabinoid JWH-018. Clin Pharmacol Ther 97:562–564

    Article  CAS  PubMed  Google Scholar 

  • Tomiyama KI, Funada M (2014) Cytotoxicity of synthetic cannabinoids on primary neuronal cells of the forebrain: the involvement of cannabinoid CB1 receptors and apoptotic cell death. Toxicol Appl Pharmacol 274:17–23

    Article  CAS  PubMed  Google Scholar 

  • Tournebize J, Gibaja V, Kahn JP (2016) Acute effects of synthetic cannabinoids: update 2015. Subst Abus 11:1–23

    Article  Google Scholar 

  • Uchiyama N, Kikura-Hanajiri R, Kawahara N, Haishima Y, Goda Y (2009) Identification of a cannabinoid analog as a new type of designer drug in a herbal product. Chem Pharm Bull 57:439–441

    Article  CAS  PubMed  Google Scholar 

  • Uchiyama N, Kikura-Hanajiri R, Goda Y (2011) Identification of a novel cannabimimetic phenylacetylindole, cannabipiperidiethanone, as a designer drug in a herbal product and its affinity for cannabinoid CB1 and CB2 receptors. Chem Pharm Bull 59:1203–1205

    Article  CAS  PubMed  Google Scholar 

  • Uchiyama N, Kawamura M, Kikura-Hanajiri R, Goda Y (2013) URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products. Forensic Sci Int 227:21–32

    Article  CAS  PubMed  Google Scholar 

  • Yamaori S, Kushihara M, Yamamoto I, Watanabe K (2010) Characterization of major phytocannabinoids, cannabidiol and cannabinol, as isoform-selective and potent inhibitors of human CYP1 enzymes. Biochem Pharmacol 79:1691–1698

    Article  CAS  PubMed  Google Scholar 

  • Yamaori S, Ebisawa J, Okushima Y, Yamamoto I, Watanabe K (2011a) Potent inhibition of human cytochrome P450 3A isoforms by cannabidiol: role of phenolic hydroxyl groups in the resorcinol moiety. Life Sci 88:730–736

    Article  CAS  PubMed  Google Scholar 

  • Yamaori S, Maeda C, Yamamoto I, Watanabe K (2011b) Differential inhibition of human cytochrome P450 2A6 and 2B6 by major phytocannabinoids. Forensic Toxicol 29:117–124

    Article  CAS  Google Scholar 

  • Yamaori S, Okamoto Y, Yamamoto I, Watanabe K (2011c) Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6. Drug Metab Dispos 39:2049–2056

    Article  CAS  PubMed  Google Scholar 

  • Yamaori S, Koeda K, Kushihara M, Hada Y, Yamamoto I, Watanabe K (2012) Comparison in the in vitro inhibitory effects of major phytocannabinoids and polycyclic aromatic hydrocarbons contained in marijuana smoke on cytochrome P450 2C9 activity. Drug Metab Pharmacokinet 27:294–300

    Article  CAS  PubMed  Google Scholar 

  • Zaitsu K, Hayashi Y, Suzuki K, Nakayama H, Hattori N, Takahara R, Kusano M, Tsuchihashi H, Ishii A (2015a) Metabolome disruption of the rat cerebrum induced by the acute toxic effects of the synthetic cannabinoid MAM-2201. Life Sci 137:49–55

    Article  CAS  PubMed  Google Scholar 

  • Zaitsu K, Nakayama H, Yamanaka M, Hisatsune K, Taki K, Asano T, Kamata T, Katagai M, Hayashi Y, Kusano M, Tsuchihashi H, Ishii A (2015b) High-resolution mass spectrometric determination of the synthetic cannabinoids MAM-2201, AM-2201, AM-2232, and their metabolites in postmortem plasma and urine by LC/Q-TOFMS. Int J Legal Med 129:1233–1245

    Article  PubMed  Google Scholar 

  • Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138:103–141

    Article  CAS  PubMed  Google Scholar 

  • Zendulka O, Dovrtelova G, Noskova K, Turjap M, Sulcova A, Hanus L, Jurica J (2016) Cannabinoids and cytochrome P450 interactions. Curr Drug Metab 17:206–226

    Article  CAS  PubMed  Google Scholar 

  • Zhou SF (2008) Drugs behave as substrates, inhibitors and inducers of human cytochrome P450 3A4. Curr Drug Metab 9:310–322

    Article  CAS  PubMed  Google Scholar 

  • Zhou SF, Zhou ZW, Yang LP, Cai JP (2009) Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem 16:3480–3675

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation of Korea (NRF) & funded by the Korean government (MSIP) (NRF-2015M3A9E1028325).

Author information

Author notes

  1. Tae Yeon Kong and Ju-Hyun Kim have contributed equally to this work.

Authors and Affiliations

  1. Drug Metabolism and Bioanalysis Laboratory, College of Pharmacy, The Catholic University of Korea, 43 Jibong-ro, Wonmi-gu, Bucheon, Gyeonggi-do, 14662, Republic of Korea

    Tae Yeon Kong, Ju-Hyun Kim, Soon-Sang Kwon & Hye Suk Lee

  2. Forensic Chemistry Laboratory, Forensic Science Division, Supreme Prosecutor’s Office, 157 Banpo-daero, Seocho-gu, Seoul, 06590, Republic of Korea

    Jae Chul Cheong, Hee Seung Kim & Moon Kyo In

Authors
  1. Tae Yeon Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ju-Hyun Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Soon-Sang Kwon
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae Chul Cheong
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Hee Seung Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Moon Kyo In
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hye Suk Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hye Suk Lee.

Ethics declarations

Conflicts of interest

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kong, T.Y., Kim, JH., Kwon, SS. et al. Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes. Arch. Pharm. Res. 40, 727–735 (2017). https://doi.org/10.1007/s12272-017-0917-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12272-017-0917-y

Keywords

Search

Navigation